300122 智飞生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.54328.95435.99178.81347.180
总资产报酬率 ROA (%)2.80918.29222.15745.10825.242
投入资产回报率 ROIC (%)4.02826.47833.58568.57227.898

边际利润分析
销售毛利率 (%)26.05026.91633.63149.03638.988
营业利润率 (%)15.24017.71322.88939.14925.642
息税前利润/营业总收入 (%)15.26717.74422.82038.99526.237
净利润/营业总收入 (%)12.79215.25019.70333.30421.733

收益指标分析
经营活动净收益/利润总额(%)119.528105.150105.691102.136104.060
价值变动净收益/利润总额(%)0.0000.0000.000-0.047-0.326
营业外收支净额/利润总额(%)-0.167-0.333-0.463-0.578-1.064

偿债能力分析
流动比率 (X)2.2632.3512.3742.0851.693
速动比率 (X)1.6391.8541.7681.4631.193
资产负债率 (%)39.02537.27936.22741.23545.787
带息债务/全部投入资本 (%)12.6898.0706.7633.289--
股东权益/带息债务 (%)681.6501,127.9531,360.2952,894.015291.924
股东权益/负债合计 (%)156.249168.247176.039142.511118.403
利息保障倍数 (X)291.724198.853632.817547.76330.334

营运能力分析
应收账款周转天数 (天)225.431162.158157.502114.4610.000
存货周转天数 (天)115.30679.153109.195124.3380.000